Breast Cancer with Neoductgenesis: Histopathological Criteria and Its Correlation with Mammographic and Tumour Features
Table 4
The correlation between neoductgenesis and patient and tumour characteristics in 74 cases with intermediate (grade 2) or high (grade 3) DCIS with or without an invasive component.
Neoductgenesis*
value
Yes () Number (%)
No () Number (%)
Age at diagnosis ()
≤55 years
10 (43.5)
19 (37.3)
0.61
>55 years
13 (56.5)
32 (62.7)
Mammographic casting type or crushed stone-like calcifications ()
Yes
20 (87.0)
28 (54.9)
0.008
No
3 (13.0)
23 (45.1)
DCIS with or without an invasive component ()
DCIS
9 (39.1)
23 (45.1)
0.63
DCIS + invasive
14 (60.9)
28 (54.9)
Cytonuclear grade ()
2
4 (17.4)
22 (43.1)
0.03
3
19 (82.6)
29 (56.9)
ER ()
Positive
8 (36.4)
45 (91.8)
<0.001
Negative
14 (63.6)
4 (8.2)
PR ()
Positive
4 (18.2)
38 (77.6)
<0.001
Negative
18 (81.8)
11 (22.4)
HER2 ()
Positive
19 (90.5)
10 (20.8)
<0.001
Negative
2 (9.5)
38 (79.2)
Ki67 ()
High
10 (47.6)
12 (25.0)
0.06
Low
11 (52.4)
36 (75.0)
Tenascin-C ()
Positive
17 (94.4)
23 (69.7)
0.04
Negative
1 (5.6)
10 (30.3)
*Neoductgenesis was defined as a total score of 17–24 between four pathologists, combining the scores for concentration of ducts (0–2), lymphocytic infiltration (0–2), and periductal fibrosis (0–2) for each pathologist.
